Publications by authors named "Antonieta Molero Yordi"
Clin Transl Sci
March 2024
Article Synopsis
- The study focused on a bispecific antibody, JNJ-67571244, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), aiming to identify maximum tolerated dose and safety outcomes.
- The phase I trial, involving 68 patients, encountered significant side effects and toxicity, with 88.2% showing treatment-emergent adverse events, while no substantial clinical responses were observed.
- The prolonged treatment strategy intended to enhance tolerability did not prevent adverse effects, and the study was terminated without achieving the planned exposure levels for determining effective dosing.
View Article and Find Full Text PDF